These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 31721154

  • 41. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
    Verma P, Dayal S, Jain VK, Amrani A.
    J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
    [Abstract] [Full Text] [Related]

  • 42. Management of Hypereosinophilic Syndromes.
    Roufosse F.
    Immunol Allergy Clin North Am; 2015 Aug; 35(3):561-75. PubMed ID: 26209900
    [Abstract] [Full Text] [Related]

  • 43. Bullous lesions at polyethylene glycol interferon-alpha-2a inoculation site in a hepatitis C virus-infected subject.
    Montesu MA, Siddi V, Satta R, Pirodda C, Cottoni F.
    Acta Derm Venereol; 2007 Aug; 87(5):433-4. PubMed ID: 17721655
    [No Abstract] [Full Text] [Related]

  • 44. [Antiviral/immunomodulatory combination therapy: pegylated interferon alpha 2a and ribavirin in patients with chronic hepatitis C virus infection].
    Delić D, Mitrović N, Popović N, Urošević A, Pešiċ I, Simonoviċ J.
    Srp Arh Celok Lek; 2012 Aug; 140(9-10):612-8. PubMed ID: 23289278
    [Abstract] [Full Text] [Related]

  • 45. Treatment of chronic hepatitis C in children with pegylated interferon α2a and ribavirin--a multi-center study.
    Słuzewski W, Kowala-Piaskowska A, Wysocki J, Figlerowicz M, Gorczyca A, Halota W, Jóźwiak H, Mizerski J, Mozer-Lisewska I, Pawłowska M, Rokitka M, Strawińska E, Szamotulska K.
    Acta Pol Pharm; 2012 Aug; 69(2):319-26. PubMed ID: 22568047
    [Abstract] [Full Text] [Related]

  • 46. FDA notifications. Renal impairment addressed in labeling.
    AIDS Alert; 2011 Nov; 26(11):131. PubMed ID: 22164522
    [No Abstract] [Full Text] [Related]

  • 47. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
    Cacopardo B, Pinzone MR, Nunnari G.
    Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
    [Abstract] [Full Text] [Related]

  • 48. New-onset psoriasis following treatment with pegylated interferon-alpha 2b and ribavirin for chronic hepatitis C.
    Horev A, Halevy S.
    Isr Med Assoc J; 2009 Dec; 11(12):760-1. PubMed ID: 20166347
    [No Abstract] [Full Text] [Related]

  • 49. Multiple Endocrine and Neoplastic Diseases After Unsuccessful Treatment of Hepatitis C With Interferon and Ribavirin.
    Attarian S, Sharma J, Kaubisch A, Zonszein J, Haigentz M.
    Am J Med Sci; 2017 Jul; 354(1):66. PubMed ID: 28755736
    [No Abstract] [Full Text] [Related]

  • 50. [Information for patients. Treatment of acute hepatitis C].
    Otón Nieto E.
    Rev Esp Enferm Dig; 2011 Oct; 103(10):549. PubMed ID: 22054273
    [No Abstract] [Full Text] [Related]

  • 51. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M, Pântea V, Cebotarescu V, Cojuhari L, Jimbei P, Albrecht J, Schmid P, Le Gal F, Gordien E, Krawczyk A, Mijočević H, Karimzadeh H, Roggendorf M, Vaillant A.
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [Abstract] [Full Text] [Related]

  • 52. [Cutaneous necrosis due to injection of interferon-alpha 2b in a patient with chronic hepatitis C].
    Castellanos González M, Pérez Carreras M, Muñoz Gómez R, Castellano Tortajada G.
    Gastroenterol Hepatol; 2011 Oct; 34(8):584-5. PubMed ID: 21641684
    [No Abstract] [Full Text] [Related]

  • 53. Feasibility of Pegylated Interferon in Children and Young Adults With Resected High-Risk Melanoma.
    Navid F, Herzog CE, Sandoval J, Daryani VM, Stewart CF, Gattuso J, Mandrell B, Phipps S, Chemaitilly W, Sykes A, Davidoff AM, Shulkin BL, Bahrami A, Furman WL, Mao S, Wu J, Schiff D, Rao B, Pappo A.
    Pediatr Blood Cancer; 2016 Jul; 63(7):1207-13. PubMed ID: 27038395
    [Abstract] [Full Text] [Related]

  • 54. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
    Klimacka-Nawrot E, Musialik J, Suchecka W, Petelenz M, Hartman M, Lichtański P, Błońska-Fajfrowska B.
    Wiad Lek; 2010 Jul; 63(4):289-99. PubMed ID: 21608370
    [Abstract] [Full Text] [Related]

  • 55. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit.
    Covic A, Maftei ID, Mardare NG, Ioniţă-Radu F, Totolici C, Tuţă L, Golea O, Covic M, Volovăţ C, Gusbeth-Tatomir P, Mircescu G.
    J Nephrol; 2006 Jul; 19(6):794-801. PubMed ID: 17173254
    [Abstract] [Full Text] [Related]

  • 56. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
    Urbanek P, Oltman M, Ivanovski L, Rehák V, Messinger D, Tietz A, Husa P.
    Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
    [Abstract] [Full Text] [Related]

  • 57. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T, Böcher WO, Biesterfeld S, Zimmermann A, Kanzler S, Greif-Higer G, Barreiros AP, Sprinzl MF, Wörns MA, Lohse AW, Mönch C, Otto G, Galle PR, Schuchmann M.
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [Abstract] [Full Text] [Related]

  • 58. Efficacy and safety of pegylated interferon base treatment in patients with chronic hepatitis C on dialysis.
    Ahn SB, Jun DW, Kim SG, Lee SH, Shin HP, Choe WH, Kim JK, Jung KS, Kim DY, Shim JJ, Park SY, Seo YS, Kim W, Chung JI.
    Eur J Intern Med; 2015 May; 26(4):292-6. PubMed ID: 25877760
    [Abstract] [Full Text] [Related]

  • 59. [Medicines for liver diseases; interferon preparations and anti-hepatitis virus agents].
    Iwasaki Y, Ikeda F, Yamamoto K.
    Nihon Rinsho; 2012 Aug; 70 Suppl 6():272-8. PubMed ID: 23156520
    [No Abstract] [Full Text] [Related]

  • 60. Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy--case report and literature review.
    Baratta L, Afeltra A, Delfino M, De Castro S, Giorgino F, Rossi-Fanelli F.
    Angiology; 2002 Aug; 53(4):465-70. PubMed ID: 12143954
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.